Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02640339 · ClinicalTrials.gov registry record
Retinal Abnormalities as Biomarker of Disease Progression and Early Diagnosis of Parkinson Disease
A clinical trial, sponsored by NYU Langone Health.
- Completed
- Registry status
- 166
- Enrollment target
NCT02640339: Completed study, sponsored by NYU Langone Health.
NCT02640339 is a clinical trial that has completed, run by NYU Langone Health. The registered enrollment target is 166 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02640339 has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 166 participants
- Enrollment target
Study Summary
* To determine whether retinal abnormalities, as measured by high definition optical coherence tomography (HD-OCT) and visual electrophysiology techniques can be used as a clinical biomarker to monitor disease progression overtime in patients with Parkinson disease. * To establish whether these measures can be used to identify patients with PD in the premotor phase. * To define the rate of progression of retinal abnormalities in PD (both in the motor and premotor stages) for potential use as a clinical outcome measure
Primary Outcome
The results of the RNFL thickness will be expressed in microns in different zones around the optic nerve: temporal, superior, nasal, inferior and global.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166 participants |
| Start Date | 2016-02 |
| Est. Completion | 2020-10-31 |
What the finished NCT02640339 record still lists
NCT02640339 is an observational study that tracks outcomes without assigning an intervention. The registered 166 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02640339 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02640339 about?
NCT02640339 is a clinical study titled "Retinal Abnormalities as Biomarker of Disease Progression and Early Diagnosis of Parkinson Disease". * To determine whether retinal abnormalities, as measured by high definition optical coherence tomography (HD-OCT) and visual electrophysiology techniques can be used as a clinical biomarker to monitor disease progression overtime in patients with Parkinson disease. * To establish whether these meas...
What is the current status of trial NCT02640339?
This trial is currently completed. The enrollment target is 166 participants. The study started on 2016-02. Estimated completion is 2020-10-31.
Who is sponsoring clinical trial NCT02640339?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02747303 · 166 participants · Phase 2
Frameless Stereotactic Radiosurgery for Intact Brain Metastases
- NCT03806283 · 166 participants
Mechanisms of Pregnancy Vascular Adaptations
- NCT04040452 · 166 participants · Phase 4
Continuous vs Intermittent Ketorolac for Pain Control in Peds CV Surgery
- NCT04375813 · 166 participants · Phase 2
Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia